Macrophage-Derived Chemokine MDC/CCL22: An Ambiguous Finding in COVID-19

Int J Mol Sci. 2023 Aug 23;24(17):13083. doi: 10.3390/ijms241713083.

Abstract

Macrophage-derived chemokine (MDC/CCL22) is a chemokine of the C-C subfamily. It is involved in T-cellular maturation and migration. Our previous research shows that plasma CCL22/MDC tends to show a statistically significant depletion of concentrations in acute patients and convalescents when compared to healthy donors. In the current work, we investigate existing views on MDC/CCL22 dynamics in association with various pathologies, including respiratory diseases and, specifically, COVID-19. Additionally, we present our explanations for the observed decrease in MDC/CCL22 concentrations in COVID-19. The first hypothesis we provide implies that viral products bind to MDC/CCL22 and block its activity. Another explanation for this phenomenon is based on dendritic cells population and the inhibition of their function.

Keywords: COVID-19; MDC/CCL22; chemokines; macrophage-derived chemokine; novel coronavirus infection; post-COVID.

MeSH terms

  • COVID-19*
  • Cell Differentiation
  • Chemokine CCL22*
  • Health Status
  • Humans
  • Plasma

Substances

  • CCL22 protein, human
  • Chemokine CCL22

Grants and funding

This research received no external funding.